FDA To Hanbul Cosmetics: You’re Marketing Noncompliant Drugs
This article was originally published in The Rose Sheet
Executive Summary
The agency’s warning letter cites the Korean firm, whose offering includes sunscreen and skin-whitening products, for violations of drug CGMP regulations. Problems identified during a recent inspection include microbiological testing failures and questions about equipment quality.